L
ow back pain is one of the most frequently encountered conditions in clinical practice (1, 2) . The most commonly prescribed medications for low back pain are nonsteroidal anti-inflammatory drugs (NSAIDs), skeletal muscle relaxants, antidepressants, and opioids (3) (4) (5) ; benzodiazepines, systemic corticosteroids, and antiseizure medications are also prescribed (3) . Patients often use over-the-counter acetaminophen and NSAIDs.
A 2007 guideline (6) and associated systematic review (7) from the American College of Physicians (ACP) and American Pain Society (APS) found evidence to support the use of acetaminophen and NSAIDs as firstline pharmacologic options for low back pain; secondary options were skeletal muscle relaxants, benzodiazepines, and antidepressants. New evidence and medications are now available. Here, we review the current evidence on benefits and harms of medications for low back pain. This article has been used by ACP to update a clinical practice guideline, also in this issue.
METHODS
Detailed methods and data for our review, including the analytic framework, additional medications (topical capsaicin and lidocaine), nonpharmacologic therapies (addressed in a separate article) (8) , search strategies, inclusion criteria, data extraction and quality-rating methods, and additional outcomes (for example, quality of life, global improvement, and patient satisfaction), are available in the full report (9) . The protocol was developed by using a standardized process (10) with input from experts and the public and is registered in the PROSPERO database (11). This article addresses the key question, what are the comparative benefits and harms of different systemic pharmacologic therapies for acute or chronic nonradicular low back pain, radicular low back pain, or spinal stenosis?
Register of Controlled Trials, and the Cochrane Database of Systematic Reviews (through April 2015). We used the prior ACP/APS review (12) to identify earlier studies. Updated searches were performed through November 2016. We also reviewed reference lists and searched ClinicalTrials.gov.
Data Extraction and Quality Assessment
One investigator extracted study data, and a second verified accuracy. For systematic reviews, we abstracted details about inclusion criteria, search strategy, databases searched, search dates, number and characteristics of included studies, quality assessment methods and ratings, synthesis methods, and results. For randomized trials, we abstracted details about the setting, sample size, eligibility criteria, population characteristics, treatment characteristics, results, and funding source.
Two investigators independently assessed the quality of each study as good, fair, or poor using criteria developed by the U.S. Preventive Services Task Force (for randomized trials) (16) and AMSTAR (A Measurement Tool to Assess Systematic Reviews) (14) .
For primary studies included in systematic reviews, we used both the quality ratings and the overall grade (for example, good, fair, or poor, or high or low) as determined in the reviews.
We classified the magnitude of effects as small/ slight, moderate, or large/substantial based on the definitions in the ACP/APS review (Table 1 ) (6, 17) . We also reported risk estimates based on the proportion of patients achieving successful pain or function outcomes (for example, >30% or >50% improvement).
Data Synthesis and Analysis
We synthesized data qualitatively for each medication, stratified according to the duration of symptoms (acute, subacute, or chronic) and presence or absence of radicular symptoms. We reported meta-analysis results from systematic reviews. When statistical heterogeneity was present, we examined the degree of inconsistency and evaluated subgroup and sensitivity analyses. We did not conduct an updated meta-analysis; rather, we qualitatively examined whether results of new studies were consistent with pooled or qualitative findings from prior systematic reviews. Qualitative assessments were based on whether the findings from the new studies were in the same direction as the prior systematic reviews and whether the magnitude of effects was similar; when prior meta-analyses were available, we analyzed whether the estimates and CIs from new studies were encompassed in the CIs from pooled estimates. We assessed the strength of evidence (SOE) for each body of evidence as high, moderate, low, or insufficient based on aggregate study quality, precision, consistency, and directness (18). Pain 5-10 points on a 0-to 100-point VAS or the equivalent 0.5-1.0 points on a 0-to 10-point numerical rating scale or the equivalent >10-20 points on a 0-to 100-point VAS or the equivalent >1-2 points on a 0-to 10-point numerical rating scale or the equivalent >20 points on a 0-to 100-point VAS or the equivalent >2 points on a 0-to 10-point numerical rating scale or the equivalent Function 5-10 points on the ODI 1-2 points on the RDQ >10-20 points on the ODI >2-5 points on the RDQ >20 points on the ODI >5 points on the RDQ
Role of the Funding Source
The Agency for Healthcare Research and Quality (AHRQ) of the U.S. Department of Health and Human Services funded this review. AHRQ staff assisted in developing the scope and key questions. The AHRQ had no role in study selection, quality assessment, or synthesis.
RESULTS

Literature Search
The search and selection of articles are summarized in the Figure. Database searches found 2847 potentially relevant articles. After dual review of abstracts and titles, we selected 746 articles for full-text dual review; 46 publications met inclusion criteria. Quality ratings are summarized in Supplement Tables 1 and 2 (available at Annals.org).
Acetaminophen
Ten trials evaluated acetaminophen; 9 of these (sample sizes, 39 to 456) were included in the ACP/APS review (19) . We identified 1 additional large (n = 1643), good-quality, placebo-controlled trial (20) . Six trials compared acetaminophen with NSAIDs and were included in a systematic review of NSAIDs (Supplement Table 3 , available at Annals.org) (21, 22) . Along with the new trial, 3 others (23-25) were rated good-or high-quality.
For acute low back pain, 1 new trial found no differences between 4 weeks or less of scheduled or asneeded acetaminophen (about 4 g/d) and placebo in pain (differences, ≤0.20 point on a 0-to 10-point scale), function (differences, ≤0.60 point on the 0-to 24-point Roland-Morris Disability Questionnaire [RDQ]), or risk for serious adverse events (about 1% in each group) after 12 weeks (Supplement Table 4 , available at Annals.org) (20) . One trial of acetaminophen versus no treatment included in the ACP/APS review (26) also found no differences.
We found no difference between acetaminophen and NSAIDs in pain intensity ( (24, 27, 28) or amitriptyline (25) ; each comparison was evaluated in 1 trial with methodological shortcomings. No study evaluated acetaminophen for chronic or radicular low back pain.
NSAIDs
Seventy trials evaluated NSAIDs; 57 were in the ACP/APS review. Sixty-five trials (total n = 11 237; sample sizes, 20 to 690), 28 of which were high-quality, were included in a systematic review (Supplement Table 3) (22) . We identified 5 additional trials (n = 54 to 525) (Supplement Table 5 , available at Annals.org) (29 -33) . One trial was rated good-quality (31), and 4 were rated fair-quality (29, 30) .
For acute back pain, 1 systematic review (22) found that NSAIDs were associated with greater mean improvements in pain intensity than placebo (4 trials: weighted mean difference, Ϫ8.39 points on a 0-to 100-point scale [CI, Ϫ12.68 to Ϫ4.10 points]; chi-square test, 3.47 points; P > 0.10) (34 -37) . One additional trial (n = 171) reported consistent findings (29) . Three trials in this review found no differences between an NSAID and placebo in the likelihood of pain relief (38 -40) . Most trials did not report effects on function, although 1 trial (41) found that NSAIDs were associated with greater improvement on the RDQ than placebo (differences, 2.4 to 2.9 points; P < 0.001).
For chronic low back pain, 1 systematic review (22) found that NSAIDs were associated with greater mean pain relief than placebo after 12 weeks (4 trials: weighted mean difference, Ϫ12.40 points on a 0-to 100-point scale [CI, Ϫ15.53 to Ϫ9.26 points]; chisquare test, 1.82 points; P > 0.50). However, 2 trials that were not included reported smaller effects on pain (0.41 to 0.59 point after 12 to 16 weeks on a 0-to 10-point scale), although NSAIDs were associated with an increased likelihood of pain relief versus placebo in both studies (≥30% pain relief: 56.8% vs. 31.7% and 37.0% vs. 27.0%; P < 0.05 in both studies) (32, 33) . Four trials found that NSAIDs were associated with no to small effects on the RDQ versus placebo (mean differences, about 0.02 to 2 points) (32, 33, 42, 43) .
For radiculopathy, the ACP/APS review (22) reported small and inconsistent effects on pain from 2 trials (36, 44) . Neither study assessed effects on function.
Evidence was insufficient to determine the effects of an NSAID plus another intervention versus this intervention alone or an NSAID versus another intervention (other interventions were a skeletal muscle relaxant, doloteffin, exercise therapy, and massage) (30, 31, 38, 45) . Each comparison was evaluated in only 1 trial with methodological shortcomings. There were no clear differences in pain relief between different NSAIDs for acute or chronic low back pain (21 and 6 trials, respectively) (22) .
The systematic review (22) found that NSAIDs were associated with more adverse effects than placebo (10 trials: RR, 1.35 [CI, 1.09 to 1.68]), although serious harms were rare. Cyclooxygenase-2-selective NSAIDs had a lower risk for adverse effects than nonselective NSAIDs (4 trials: RR, 0.83 [CI, 0.70 to 0.99]).
Opioids, Tramadol, and Tapentadol
Twenty-seven trials (sample sizes, 21 to 981) evaluated opioids, tramadol (a dual-action analgesic with weak opioid μ-receptor affinity), or tapentadol (a dualaction analgesic with strong μ-receptor affinity) versus placebo or other treatments; 14 were included in the ACP/APS review and 16 (13 rated low risk of bias) were reported in a systematic review (Supplement Table 3 ) (46) . Three trials (1 higher-quality) (47) were included in the ACP/APS review (47) (48) (49) . We identified 8 additional trials (Supplement Table 6 , available at Annals.org) (50 -57): 2 good-quality (50, 51), 5 fair-quality (53-57), and 1 poor-quality (52) . Methodological shortcomings included high attrition (30% to 60% in most trials), use of an enriched enrollment randomized withdrawal design (58) by some trials (47, 52, 56, 57, 59 -64) , and short follow-up (maximum of 16 weeks) (48) . We also identified 11 trials that compared opioids. Eight trials (47, 48, (65) (66) (67) (68) (69) (70) were included in a systematic review (71) , but 3 others were not (72) (73) (74) .
For acute low back pain, 1 trial found no difference between oxycodone or acetaminophen plus naproxen (n = 108) and placebo plus naproxen (n = 107) in pain or function (54) .
For chronic low back pain, 1 systematic review (46) found that strong opioids (morphine, oxymorphone, hydromorphone, and tapentadol) were associated with greater short-term relief than placebo for pain (6 The review (46) found that opioids had a higher risk for nausea, dizziness, constipation, vomiting, somnolence, and dry mouth than placebo. Trials were not designed to assess long-term harms or the risk for overdose, abuse, or addiction.
For symptomatic spinal stenosis, a small (n = 21) trial found no differences between single-dose immediate-release oxymorphone and placebo in pain, function, or other outcomes (55) .
Four trials found no clear differences among various long-acting opioids in pain or function (47, 65, 66, 72, 74). Six trials found no clear differences between † Other sources include prior reports, reference lists of relevant articles, and systematic reviews. ‡ Publications may be included or excluded for multiple reasons.
long-and short-acting opioids in pain (48, (67) (68) (69) (70) 73) . Although some trials found long-acting opioids associated with greater pain relief, patients randomly assigned to these drugs also received higher doses.
Skeletal Muscle Relaxants
Twenty-five trials (sample sizes, 20 to 562) evaluated skeletal muscle relaxants; 22 (17 high-quality) were included in a systematic review (Supplement Table 3) (79) used in the ACP/APS review. We identified 3 additional fair-quality trials (Supplement Table 7 , available at Annals.org) (54, 80, 81) .
For acute low back pain, the systematic review (79) found skeletal muscle relaxants superior to placebo for short-term pain relief (≥2-point or 30% improvement on a 0-to 10- (79) . Evidence was insufficient from 3 small placebocontrolled trials with inconsistent results and methodological shortcomings to determine the effects of skeletal muscle relaxants on chronic low back pain (82) (83) (84) . Four trials showed inconsistent effects of a skeletal muscle relaxant plus an NSAID versus an NSAID alone (54, 79, 80) . Although estimates from 3 trials favored the combination for effects on pain intensity, the fourth trial found no effects on pain or function (54) . Three trials in the review (79) found no differences among various skeletal muscle relaxants on any outcome (85) (86) (87) .
Benzodiazepines
Nine trials (sample sizes, 30 to 152) evaluated benzodiazepines; 8 of these trials (5 high-quality) were included in a systematic review (79) used in the ACP/APS review (Supplement Table 3 ). The ninth, a good-quality trial (n = 60) (Supplement Table 8 , available at Annals .org), evaluated benzodiazepines for radicular pain (88) .
For acute nonradicular low back pain, 2 trials reported inconsistent effects of benzodiazepines versus placebo (89, 90) ; the higher-quality trial (n = 50) (89) found no difference between diazepam and placebo in the likelihood of reduced pain and tenderness at 5 days (76% vs. 72%; RR, A systematic review (79) found that compared with placebo, benzodiazepines were associated with greater risk for central nervous system adverse events, such as somnolence, fatigue, and lightheadedness, although harms were not well-reported. No trial was designed to evaluate risk for addiction, abuse, or overdose.
Antidepressants
Sixteen trials (n = 16 to 404) evaluated antidepressants; 7 were used in the ACP/APS review, and 10 trials (7 high-quality) were included in a systematic review (Supplement Table 3 ) (95). We identified 6 additional trials (Supplement Table 9 , available at Annals .org): 1 good-quality (96), 3 fair-quality (97-99), and 2 poor-quality (100, 101). Two trials required patients to have depression and low back pain (102, 103 Three trials not in that review found that the serotonin norepinephrine reuptake inhibitor duloxetine, 60 mg/d, was associated with lower pain intensity at 12 to 13 weeks, although effects were small (differences, 0.60 to 0.79 point on the 0-to 10-point Brief Pain Inventory severity scale) (96 -98) . One trial of duloxetine also found an increased likelihood of 50% or greater pain relief after 12 weeks (49% vs. 35%; RR, 1.41 [CI, 1.11 to 1.78]) (97) . All 3 trials found that duloxetine was associated with greater improvement in function than placebo on the Brief Pain Inventory interference scale (mean between-group difference, 0.58 to 0.74 point), but 1 trial found no difference on the RDQ (mean change from baseline, Ϫ2.69 vs. Ϫ2.22 points; P = 0.26) (97). There were no differences between duloxetine and placebo in the risk for serious adverse events (96 -98) , although duloxetine was associated with increased risk for withdrawal due to adverse events (3 trials: odds ratio, 2.72 [CI, 1.74 to 4.24]; I 2 = 0%). Duloxetine was associated with increased risk for nausea (P < 0.05).
Evidence to directly compare serotonin norepinephrine reuptake inhibitors with other antidepressants was very limited. One fair-quality trial (n = 85) found no differences between duloxetine and escitalopram (a selective serotonin reuptake inhibitor) in pain or function (96, 99) . One small trial (n = 25) provided insufficient evidence to determine the effects of duloxetine for radicular pain (101).
Antiseizure Medications
Twelve trials (n = 29 to 309) evaluated antiseizure medications; 4 (104 -107) were reported in the ACP/ APS review (Supplement Table 3 ). We identified 8 additional trials (Supplement Table 10 , available at Annals .org) (108 -115) . Seven of these (108 -113, 115) evaluated pregabalin and 1 (114) evaluated gabapentin. Of the 12 antiseizure medication trials, 6 (106, 108, 109, (111) (112) (113) were rated fair-quality and 6 (104, 105, 107, 110, 114, 115) were rated poor-quality.
No trial evaluated antiseizure medications for acute low back pain. For chronic nonradicular back pain, 2 fair-quality trials found that pregabalin was associated with no effects on pain intensity versus placebo (differences, 0.14 to 0.21 point on a 0-to 10-point scale) (108, 111) . One trial found no effect on function on the Oswestry Disability Index (ODI) (108) , and the other found that pregabalin had slightly worse scores on the RDQ (13 vs. 11 points; P = 0.01) (111) . Evidence was insufficient to determine adverse effects of topiramate or pregabalin versus placebo because of inconsistent findings.
For chronic radicular back pain, 3 poor-quality trials reported inconsistent findings for gabapentin (dose titrated up to 1200 to 3600 mg/d) versus placebo (105, 107, 114) . Effects on pain intensity ranged from 0.3 to 1.9 points on a 0-to 10-point scale. One fair-quality and 1 poor-quality trial reported inconsistent effects of topiramate, with small to moderate effects on some measures of pain (104, 106) ; no effects on leg pain or the ODI were reported in 1 of the trials (106) .
Evidence was insufficient from single trials with methodological shortcomings to determine the effects of pregabalin versus other medications (110, 113, 115) or pregabalin plus another medication versus the other medication alone (109, 112, 113) .
Systemic Corticosteroids
Ten trials (sample size, 29 to 269) evaluated systemic corticosteroids; 4 (116 -119) were included in the ACP/APS review (Supplement Table 3 ). We identified 6 additional trials (Supplement Table 11 , available at Annals.org) (120 -125) . Treatment ranged from a single dose to a 21-day course; corticosteroid doses varied. Eight trials evaluated patients with radiculopathy; of these, 3 (116, 124, 125) required imaging correlation. Four trials (116, 117, 121, 125) were rated goodquality, 5 fair-quality (118 -120, 122, 124) , and 1 poorquality (123) .
For acute nonradicular low back pain, 2 trials (n = 86 and 67) found no differences between a single intramuscular injection or a 5-day course of systemic corticosteroids and placebo in pain or function (117, 120) . For spinal stenosis, 1 trial (n = 61) found no differences through 12 weeks of follow-up between a 3-week course of prednisone and placebo in pain intensity or the RDQ (124) . No trial evaluated systemic corticosteroids for chronic nonradicular pain.
For radicular low back pain of varying duration, 6 trials consistently found no differences between systemic corticosteroids and placebo in pain (116, 118, 119, 121, 123, 125) . For function, the largest (n = 269) good-quality trial found that systemic corticosteroids were associated with small effects (difference in ODI at 52 weeks, 7.4 [CI, 2.2 to 12.5]) (125), but 2 other trials found no effects (121, 123) . Two trials found no effects of systemic corticosteroids on the likelihood of spine surgery (116, 125) .
In the largest trial, oral prednisone (initial dose, 60 mg/d) increased risk for any adverse event (49% vs. 24%; P < 0.001), insomnia (26% vs. 10%; P = 0.003), nervousness (18% vs. 8.0%; P = 0.03), and increased appetite (22% vs. 10%; P = 0.02) (125) . A smaller (n = 39) trial found that a tapering course of intramuscular dexamethasone (initial dose, 64 mg/d) was associated with increased risk for any adverse effect (32% vs. 5.0%; RR, 6.32 [CI, 0.84 to 47.7]), but there were no withdrawals due to adverse events (122) . Serious harms were not reported in any trial, but harms were not well-reported in some trials.
DISCUSSION
Many systemic pharmacologic therapies have some evidence of effectiveness in acute ( Table 2 and  Supplement Table 12 , available at Annals.org) or chronic low back pain ( Table 3 and Supplement Table  13 , available at Annals.org). Benefits were generally observed for short-term (generally <3 months) pain and were small (5 to 10 points on a 100-point VAS) to moderate (10 to 20 points), based on the ACP/APS categories (19) . Function was reported less consistently than pain, and effects were typically smaller or not observed. Evidence on other outcomes (for example, quality of life, mood, work, analgesic use, or health care use) was sparse and is described in the full report (9) . As in the ACP/APS review, evidence on pharmacologic therapies for radiculopathy was very limited ( Table 4) . The SOE ratings are summarized in Supplement Table  14 (available at Annals.org). New evidence affected findings for several medications. The ACP/APS review concluded that acetaminophen was effective for acute low back pain, primarily based on trials showing similar effectiveness of acetaminophen compared with NSAIDs. However, the first large, well-conducted, placebo-controlled trial found that acetaminophen was ineffective for acute low back pain (low SOE) (20) . Newer trials reported that NSAIDs had smaller benefits than placebo for chronic low back pain than previously observed (32, 33) . For antidepressants, several trials found duloxetine, a serotonin norepinephrine reuptake inhibitor introduced after the prior ACP/APS review, to be more effective than placebo for chronic low back pain, although effects were small (moderate SOE) (96 -98) . Previous reviews found that tricyclic antidepressants were modestly effective for chronic low back pain; however, a meta-analysis with newer trials found no differences versus placebo (moderate SOE) (95) . For antiseizure medications, new placebo-controlled trials on pregabalin for radicular low back pain are available but had methodological shortcomings and reported inconsistent results (insufficient SOE) (108, 111) . A recent trial on radiculopathy found that compared with placebo, benzodiazepines were associated with no difference in function but more pain (low SOE) (88) .
Other conclusions were relatively unchanged. Skeletal muscle relaxants relieved short-term acute low back pain but caused sedation (moderate SOE). Systemic corticosteroids do not seem to be effective for radicular or nonradicular low back pain in improving pain (moderate SOE), although a recent trial reported small effects on function (125) . Evidence on benzodiazepines for nonradicular back pain remains sparse (insufficient SOE) (23) . For opioids, evidence remains limited to short-term trials showing modest effects versus placebo for chronic low back pain (moderate SOE) (46) . Trials were not designed to assess the risk for overdose or opioid use disorder because of relatively small samples, short follow-up, and exclusion of higher-risk patients; in addition, many studies used an enriched enrollment randomized withdrawal design, which could (127) . For nonopioid medications, serious harms were generally not observed, although the studies were not designed to assess uncommon or longer-term harms.
Relatively few studies compared the effectiveness of different medications for low back pain or a combination of 2 medications versus 1 medication alone. There were no clear differences between opioids and NSAIDs, benzodiazepines and skeletal muscle relaxants, or acetaminophen and NSAIDs.
We categorized the magnitude of effects for pain and function using the thresholds in the ACP/APS review ( Table 1 ). Effects that were classified as small (for example, 5 to 10 points on a 0-to 100-point scale for pain or function) are below some of the proposed thresholds for the minimum clinically important difference (for example, 15 points on a 0-to 100-point VAS for pain, 2 points on a 0-to 10-point numerical rating scale for pain or function, 5 points on the RDQ, and 10 points on the ODI) (17) . Factors that may support the use of interventions associated with small effects include low risk for harms, low costs, or strong patient preferences; in addition, some patients will have greater-than-average effects. The magnitude of effects might vary depending on baseline severity (128); most trials enrolled patients with at least moderate pain (for example, >5 points on a 0-to 10-point numerical rating scale).
Our findings have implications for clinical practice. Guidelines currently recommend acetaminophen as a first-line option for acute and chronic low back pain (6, 129) . The use of opioids for chronic pain has become an area of increasing concern (130) . Since the ACP/APS guideline was published, the antidepressant duloxetine has been approved by the U.S. Food and Drug Administration for low back pain and seems to be more effective and safer than tricyclic antidepressants.
Our review has limitations. Reviewing all primary literature was not feasible because of the large number of medications addressed. We included higher-quality, recent systematic reviews that were most relevant to the scope of our review (131), supplemented with additional primary trials. Although we did not update meta-analyses reported in systematic reviews, we evaluated the consistency of results from new trials against prior pooled estimates. We excluded non-Englishlanguage articles and did not search for abstract-only publications. Some systematic reviews that we used included such articles but did not affect our conclusions. Our ability to assess for publication bias was limited because of methodological limitations in the trials and study heterogeneity and because few trials were available for many comparisons. Although we did not include new or updated systematic reviews identified in update searches (132-134), we used these searches to identify additional trials. Our findings were generally concordant with new reviews. We did not evaluate the effectiveness of medications injected for local effects; epidural steroid injections were recently reviewed elsewhere (135) .
The evidence base has limitations. Effects on pain and function were typically reported as mean differences. Few studies reported the likelihood of clinically significant improvements (136) . Data were sparse for several medications, and many studies had methodological flaws. Some studies did not clearly describe important patient characteristics, such as the duration of symptoms, presence of radiculopathy, or use of cointerventions. Older adults were underrepresented, and most antidepressant trials excluded or included few patients with depression (95) . Therefore, evidence to determine how medication effectiveness varies in important subgroups is lacking. Most studies were funded by industry. For example, all placebo-controlled trials of duloxetine for nonradicular low back pain were funded by the manufacturer and nearly all trials of opioids were industry-funded.
More research is needed to determine effective treatments for radicular low back pain. Trials with longer-term follow-up are needed to help understand whether benefits are sustained. Studies are particularly needed on the long-term effectiveness and harms of opioids for chronic low back pain in clinically representative populations. More research is also needed to better understand whether combining medications is associated with incremental benefits and which combinations and sequences of medications are the most effective. Trials should routinely assess important outcomes, such as mood, quality of life, return to work, and health care use, and more consistently and rigorously evaluate and report harms.
In conclusion, several systemic pharmacologic therapies for low back pain are associated with small to moderate, primarily short-term effects on pain. Effects on function were generally smaller than effects on pain. New evidence suggests that acetaminophen is ineffective for acute low back pain and that duloxetine is associated with modest effects for chronic low back pain. More research is needed to understand the optimal selection of medications, the best combinations and sequencing of treatments, and the most effective medications for radicular low back pain.
